Skip to content
Daniel Zank

Dr. Daniel Zank is a fellowship-trained pulmonologist who treats all lung diseases, including sarcoidosis.



Education


Education

2006 - 2010
Loyola University of Chicago Stritch School of Medicine, Maywood, IL, MD
2004 - 2006
University of Wisconsin, Madison, WI, MS, Population Health Sciences
1998 - 2002
University of Wisconsin, Madison, WI, BS, Biology

Internships

2010 - 2011
University of California - San Diego, La Jolla, CA, Internal Medicine

Residency

2011 - 2013
University of Michigan, Ann Arbor, MI, Internal Medicine

Fellowship

2015 - 2018
University of Pittsburgh, Pittsburgh, PA, Division of Pulmonary, Allergy & Critical Care Medicine

Awards & Recognition


2011: University of California-San Diego, Intern of the Year
2017-2018: T32 Ruth L. Kirschstein, National Research Service Award

Board Certification


2013: American Board of Internal Medicine, Internal Medicine
2017: American Board of Internal Medicine, Pulmonary Medicine
2018: American Board of Internal Medicine, Critical Care Medicine

Professional Memberships


2011-Present: American Medical Association
2013-Present: American College of Physicians
2015-Present: American Thoracic Society

Publications


Bueno M, Zank DC, Buendia-Roldan I, et al. PINK1 attenuates mtDNA release in alveolar epithelial cells and TLR9 mediated profibrotic responses. JCI Insight, 2019, Accepted Submission.

Zank DC, Bueno M, Mora AL, Rojas M. Idiopathic pulmonary fibrosis: Aging, mitochondrial dysfunction, and cellular bioenergetics. Front Med (Lausanne) 2018;5. doi:10.3389/fmed.2018.00010.

Fendrick AM, Zank D. Value-Based Insurance Design: Aligning incentives and evidence in pulmonary medicine. Chest, 2013; 144(5): 1712-6.

Robles L, Slogoff M, Ladwig-Scott E, Zank D, Larson MK, Aranha G, Shoup M. The addition of a nurse practitioner to an inpatient surgical team results in improved use of resources. Surgery, 2011; 150(4): 711-7.

Freeberg SY, Maglione T, Amin A, Zank D, Heroux AL, et al. Efficacy of mechanical circulatory support devices for termination of drug-refractory sustained ventricular tachycardia. J Clinic Experiment Cardiol, 2011; 2: 153.